Tag Archive for: satoreotide

Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024

/in

SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple times more potent than SST2 agonist, 225Ac-DOTATATE Satoreotide demonstrated durable complete response in standard murine xenograft models of Small Cell Lung Cancer in animal models, versus tumor growth delay with 225Ac-DOTATATE Berlin, Germany, 10 June, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of […]

Read more

Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

/in

95% of patients (36 of 38) treated with Ariceum’s radiopharmaceutical satoreotide achieved disease control in Phase I/II trial That included 21% of patients (8 of 38) who experienced tumour reduction The study, just published in the European Journal of Nuclear Medicine and Molecular Imaging, concluded the treatment “has an acceptable safety profile with a promising […]

Read more

Ariceum Therapeutics Q4 2022 Investor and Scientific Conference

/in

BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, today announces that its senior management team will be attending and hosting meetings at the following investor and scientific conferences in the fourth quarter of 2022. Read more…

Read more

Ariceum Therapeutics Appoints Chief Business Officer

/in

BERLIN, 7 July 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Serge Sagodira as Chief Business Officer. Appointed from 1 July 2022, Serge will oversee all business development aspects of the company, leveraging […]

Read more

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

/in

Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures Developing novel drugs for systemic targeted radiation therapy (STRT) Proceeds will be used to advance lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers Led by industry veteran Manfred Rüdiger as CEO, and world-renowned […]

Read more